Enveric Biosciences, Inc. (NASDAQ:ENVB) Short Interest Update

Enveric Biosciences, Inc. (NASDAQ:ENVB) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 46,331 shares, a growth of 74.3% from the May 31st total of 26,583 shares. Based on an average daily trading volume, of 270,136 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ENVB shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of Enveric Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, June 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Enveric Biosciences has an average rating of “Sell”.

Enveric Biosciences Stock Down 3.3%

NASDAQ:ENVB opened at $1.45 on Friday. The company has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $2.72. The company has a market cap of $5.34 million, a price-to-earnings ratio of -0.06 and a beta of 1.15. Enveric Biosciences has a 52 week low of $1.26 and a 52 week high of $17.64.

Enveric Biosciences (NASDAQ:ENVB) last announced its quarterly earnings data on Friday, May 15th. The company reported ($1.08) earnings per share (EPS) for the quarter.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.